MedTrace Logo

An Observational Study of Epoetin Beta [Neorecormon] to Evaluate the Quality of Life in Patients on Dialysis With Chronic Renal Anemia

NCT01105494 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6000

Last updated 2012-09-13

No results posted yet for this study

Summary

This multicenter, prospective, observational study will evaluate the quality of life and the factors that influence the quality of life of epoetin beta \[Neorecormon\] in patients with renal chronic anemia, who are on dialysis. For each eligible patient data will be collected for 6 months. Target sample size is 5000-7000 patients.

Conditions

Interventions

DRUG

epoetin beta [NeoRecormon]

As prescribed by physician

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • Morocco

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01105494 on ClinicalTrials.gov